Loading clinical trials...
Loading clinical trials...
ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES
Conditions
Interventions
Elranatamab
Locations
28
United States
UCHealth Poudre Valley Hospital
Fort Collins, Colorado, United States
UCHealth Harmony
Fort Collins, Colorado, United States
UCHealth Greeley Hospital
Greeley, Colorado, United States
Longs Peak Hospital
Longmont, Colorado, United States
UCHealth Longs Peak Medical Center
Longmont, Colorado, United States
UCHealth - Medical Center of the Rockies
Loveland, Colorado, United States
Start Date
October 3, 2023
Primary Completion Date
February 22, 2032
Completion Date
February 22, 2032
Last Updated
April 16, 2026
NCT06679101
NCT05969860
NCT06383143
NCT06870760
NCT05243797
NCT07452198
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions